menu
    • menu

    Company profile for Antengene

    NEW Drugs in Dev: 14
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Antengene Corporation is a clinical-stage biopharmaceutical company that focuses on introducing cutting-edge treatments, ranging from early-to-late stage development pipelines to mature brands, to China and other Asian markets. With clinical development and regulatory expertise as well as local market knowledge in Asia Pacific, Antengene collaborates with academic research institutions and leading biotech companies around the ...
    Antengene Corporation is a clinical-stage biopharmaceutical company that focuses on introducing cutting-edge treatments, ranging from early-to-late stage development pipelines to mature brands, to China and other Asian markets. With clinical development and regulatory expertise as well as local market knowledge in Asia Pacific, Antengene collaborates with academic research institutions and leading biotech companies around the world on diseases with higher incidence and urgent needs in China and other Asia Pacific countries/regions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AntengeneChina Flag
    Country
    Country
    China
    Address
    Address
    Suite 704, 999 West Zhongshan Road, Shanghai
    Telephone
    Telephone
    +86 21 3250 1095
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.antengene.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    UCB enters TCE space with $1.1B Deal for Autoimmune Candidate
    UCB enters TCE space with $1.1B Deal for Autoimmune Candidate

    05 Mar 2026

    // PRESS RELEASE

    https://www.ucb.com/newsroom/press-releases/article/ucb-and-antengene-enter-global-license-agreement-for-atg-201-a-b-cell-depleting-bispecific-antibody

    PRESS RELEASE
    05 Mar 2026
    Share Share
    Antengene and UCB Enter Global License Agreement for ATG-201
    Antengene and UCB Enter Global License Agreement for ATG-201

    04 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-and-ucb-enter-global-license-agreement-for-atg-201-a-cd19cd3-bispecific-t-cell-engager-for-autoimmune-diseases-302702638.html

    PR NEWSWIRE
    04 Mar 2026
    Share Share
    XPOVIO® Gains Reimbursement Approval in 2nd-Line Multiple Myeloma
    XPOVIO® Gains Reimbursement Approval in 2nd-Line Multiple Myeloma

    01 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xpovio-receives-reimbursement-approval-in-south-korea-for-a-second-multiple-myeloma-indication-302700200.html

    PR NEWSWIRE
    01 Mar 2026
    Share Share
    Antengene Highlights Clinical Data and ADC, TCE Strategy at JPM
    Antengene Highlights Clinical Data and ADC, TCE Strategy at JPM

    15 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662551.html

    PR NEWSWIRE
    15 Jan 2026
    Share Share
    Malaysia Approves Antengene's XPOVIO for DLBCL Treatment
    Malaysia Approves Antengene's XPOVIO for DLBCL Treatment

    16 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-expands-xpovio-indications-in-malaysia-with-approval-in-diffuse-large-b-cell-lymphoma-302643379.html

    PR NEWSWIRE
    16 Dec 2025
    Share Share
    Antengene Unveils ATG-201 Preclinical Data At ACR 2025
    Antengene Unveils ATG-201 Preclinical Data At ACR 2025

    27 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-presents-latest-preclinical-data-of-atg-201-cd19-x-cd3-tce-at-acr-2025-302593950.html

    PR NEWSWIRE
    27 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search